RevMed partners with BeOne for Asian rights to RAS drugs as MoonLake reports Phase 3 success
read at Endpoints ↗DealPositive
RevMed and BeOne have entered a partnership granting BeOne rights to commercialize RevMed’s RAS pathway drugs in selected Asian markets.
The agreement also includes collaboration on upcoming clinical trials for those candidates.
In related news, MoonLake Therapeutics announced that its Phase 3 trial met primary endpoints, marking a positive development for the company.
The brief also noted activity from other firms such as Avere Therapeutics, Novo Nordisk, Sobi, Innate Pharma, Oculis, Innovent Biologics and Daiichi Sankyo, though no further details were provided.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “RevMed, BeOne make clinical trial, Asia deal; MoonLake reports Phase 3 win”
read at Endpoints ↗81 words · retrieved Aug 10
comments(0)
5-min edit window · permanent after that